Osaka, Japan, October 10, 2024 - Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) today announced that it has entered into a license agreement with LigaChem Biosciences, Inc. (Daejeon, South Korea; CEO: Yong-Zu Kim; 'LCB') for LCB97, a pre-clinical stage antibody-drug conjugate (ADC) (“this Agreement”) aimed at being a first-in-class drug in the field of solid tumors, as well as a research collaboration and license agreement to generate novel ADC candidates by leveraging LCB’s proprietary ConjuAll™ ADC platform..

日本大阪，2024年10月10日-小野制药有限公司（总部：日本大阪；总裁：Toichi Takino；“小野”）今天宣布，它已与LigaChem Biosciences，Inc.（韩国大田；首席执行官：Yong Zu Kim；“LCB”）签订了LCB97的许可协议，LCB97是一种临床前阶段抗体-药物偶联物（ADC）（“本协议”），旨在成为实体瘤领域的一流药物，以及一项研究合作和许可协议，通过利用LCB专有的ConjuAll™ADC平台生成新的ADC候选药物。。

LCB97 is an ADC generated and developed by leveraging LCB’s proprietary ConjuAll™ ADC platform, targeting at L1 cell adhesion molecule (L1CAM) which has been reported to be highly expressed in multiple solid tumors. LCB97 has demonstrated strong anti-tumor effects in various mouse cancer models conducted so far by LCB..

LCB97是利用LCB专有的ConjuAll™ADC平台生成和开发的ADC，靶向据报道在多种实体瘤中高度表达的L1细胞粘附分子（L1CAM）。。。

Under this Agreement, Ono will have an exclusive worldwide right to develop, manufacture and commercialize LCB97 for solid tumors. Ono will make an upfront payment to LCB, along with milestone payments based on research and development progress and sales, up to a maximum of 700 million US dollars, as well as tiered royalties based on net sales..

根据该协议，小野将拥有开发、制造和商业化用于实体瘤的LCB97的全球独家权利。小野将向LCB支付预付款，以及基于研发进度和销售额的里程碑付款，最高可达7亿美元，以及基于净销售额的分层版税。。

In addition to this Agreement, Ono and LCB have separately entered into research collaboration and license agreement to generate novel ADC candidates by leveraging LCB's ConjuAll™ ADC platform. Under the agreement, Ono will have an exclusive global right to the ADC candidates to be generated against multiple targets selected by Ono by utilizing LCB’s ConjuAll™ ADC platform.

除此协议外，Ono和LCB还分别签订了研究合作和许可协议，以利用LCB的ConjuAll™ADC平台生成新的ADC候选产品。根据该协议，Ono将拥有利用LCB的ConjuAll™ADC平台针对Ono选择的多个目标生成ADC候选者的独家全球权利。

Ono will pay LCB a target exclusive fee along with milestone payments based on research and development progress and sales, as well as tiered royalties based on net sales..

小野将向LCB支付目标独家费用，以及基于研发进度和销售额的里程碑付款，以及基于净销售额的分层版税。。

'We are delighted to partner with LCB to provide new treatment options for patients with solid tumors. LCB’s ADC technology holds the potential to revolutionize cancer treatment and strengthen our oncology portfolio. We look forward to working closely with LCB to bring innovative therapies to patients as quickly as possible,' said Seishi Katsumata, Corporate Officer / Executive Director, Discovery & Research of Ono..

“我们很高兴与LCB合作，为实体瘤患者提供新的治疗选择。LCB的ADC技术有可能彻底改变癌症治疗并加强我们的肿瘤学组合。“我们期待着与LCB密切合作，尽快为患者带来创新疗法，”小野的发现与研究公司高管/执行董事Seishi Katsumata说。。

'We are thrilled that our partnership with Ono will enable our ADC technology to reach cancer patients worldwide. With Ono's extensive experience and expertise, we are confident in advancing our ADC cancer therapy. This collaboration opens new possibilities in cancer treatment,' said Yong-Zu Kim, CEO of LCB..

。凭借大野的丰富经验和专业知识，我们有信心推进ADC癌症治疗。LCB首席执行官金永祖（Yong Zu Kim）说，这种合作为癌症治疗开辟了新的可能性。。

The impact of this matter on the Company’s consolidated financial results for the current fiscal year ending March 31, 2025, is expected to be minor. Should there be any events to be disclosed in the future, we will announce them in a timely manner.

预计该事项对截至2025年3月31日的本财年公司合并财务业绩的影响较小。如果将来有任何需要披露的事件，我们将及时公布。

About ConjuAll™ ADC platform technologies

关于ConjuAll™ADC平台技术

ConjuAll™ ADC platform technologies overcome the existing limitations of ADCs by imparting a trinity of improved properties, (1) site-specific stable bioconjugation (2) cancer selective linker activation and (3) cancer-selective activation of potent payload, all of which in a significantly broader therapeutic window.

ConjuAll™ADC平台技术通过赋予三位一体的改进特性来克服ADC的现有局限性，（1）位点特异性稳定的生物缀合（2）癌症选择性接头激活和（3）有效载荷的癌症选择性激活，所有这些都在一个显着更广泛的治疗窗口。

This technology enables effective targeting of cancer cells while minimizing damage to normal cells..

这项技术能够有效靶向癌细胞，同时最大程度地减少对正常细胞的损伤。。

About LigaChem Biosciences, Inc.

关于LigaChem Biosciences, Inc.

LigaChem Biosciences, Inc. (LCB) is a clinical stage biopharmaceutical company dedicated to the discovery and development of innovative medicines by leveraging the medicinal chemistry expertise to make conventional biologics more targeted and potent for the benefit of patients with diseases of highly unmet medical needs.

LigaChem Biosciences，Inc.（LCB）是一家临床阶段的生物制药公司，致力于通过利用药物化学专业知识发现和开发创新药物，使常规生物制剂更有针对性和有效性，以造福于高度未满足医疗需求的疾病患者。

LCB is advancing sustainable pipelines in therapeutic areas within antibiotics, anti-fibrotics, oncology, and ADC platform technology.

LCB正在推进抗生素、抗纤维化、肿瘤学和ADC平台技术治疗领域的可持续管道。